Clinical Trial

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-08-24; most recent amendment 2026-02-01.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-09-08
Status change: Recruiting → Enrolling by Invitation 2024-10-11
Status change: Not Yet Recruiting → Recruiting 2022-11-16
Trial Details
NCT Number NCT05518045
Lead Sponsor LaNova Medicines Limited
Conditions Advanced Solid Tumor
Enrollment 392 participants
Start Date 2022-08-26
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-04